Economic Assessment of ANDHealth+ and Masterclass: Accelerate Programs
Posted: 20 February 2024 An independent report into Australian digital health commercialisation programs has highlighted the considerable impact of ANDHealth on core economic metrics when benchmarked against comparable accelerators in general technology, deep technology, and health technology. Published…
OPTISCAN RECEIVES $3 MILLION CRC-P INDUSTRY GRANT
Posted: 14 February 2024 Optiscan Imaging Limited (ASX: OIL) is pleased to announce receiving a $3 million Cooperative Research Centres Projects (CRC-P) grant to work on its Edge-AI-enabled gastrointestinal (GI) endomicroscope. The project worth a total of $9,236,713…
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Posted: 14 February 2024 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of…
Noxopharm extends strategic partnership with Hudson Institute of Medical Research
Posted: 14 February 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that it has renewed its strategic partnership with Melbourne’s Hudson Institute of Medical Research for a further 12 months. The partnership and in-licensed technology…
Navigating the Australian Medtech Market
Posted: 13 February 2024 Welcome to ‘Navigating the Australian Medtech Market’ a guide designed for new SMEs entering the Australian healthcare market. This guide is designed to illuminate the pathways to success within the Australian healthcare landscape. Towards…
It’s a match: New drug discovered to target protein in CNS disorders
Posted: 12 February 2024 Research by The Florey’s Drug Discovery Innovation Group has identified a new, highly specific drug, Cpd1, which can help scientists understand what types of diseases and illnesses the cell-surface protein ‘α1B-adrenoceptor’ may be responsible for. The…
Nose-like sensor sniffs out toxic ammonia gas
Posted: 12 February 2024 Engineers in Australia have developed a small ammonia gas sensor that could enable safer hydrogen storage and specialised medical diagnostic devices. The simple yet effective proof-of-concept sensor described in top academic journal Advanced Functional Materials is…
Diet breakthrough: Monash University researchers find simpler alternative to intermittent fasting
Posted: 12 February 2024 Monash University scientists have identified a less stringent and more manageable alternative to traditional intermittent fasting, offering new possibilities for extending lifespan and promoting healthy ageing. This novel method, involving short-term isoleucine deprivation, has…
Ichor Clinical partners with CROs in Australia, Ireland and UK
Posted: 12 February 2024 Ichor Life Sciences has established operations in Australia, Ireland, and the UK by partnering with local contractors. The move saw US clinical research organization (CRO) Ichor establish collaborative service offerings with “concierge and boutique”…
One step closer to a blood test for diagnosing Alzheimer’s
Posted: 12 February 2024 A Melbourne study showing the efficacy of a simple blood test to detect the earlier stages of Alzheimer’s has brought us one step closer to a ‘game-changer’ for dementia diagnostics. Australian Dementia Network (ADNeT)…
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
Posted: 12 February 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its…
Five Victorian Cancer Agency grants awarded to Peter Mac Researchers
Posted: 12 February 2024 In alignment with World Cancer Day, Minister for Health Mary-Anne Thomas announced funding for 13 Victorian Cancer Agency fellowships with Peter Mac researchers receiving almost half of the fellowships. The fellowships covered low-survival cancers,…
